Loading stock data…
Alumis Inc. (ALMS)
$11.10-0.26 (-2.29%)
Pre-Market$11.01-0.09 (-0.81%)· Last close Sep 4
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alumis Inc. in the Healthcare sector is trading at $11.10 with a market capitalization of $2.6B. Wall Street consensus targets $32.12 (8 analysts), implying a +189.4% move over the next 12 months. The stock is currently 65% below its 52-week high of $31.35, remaining 50.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +189.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 18) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.74M↓ | $1.93M↓ | $2.07M↓ | $2.67M↓ | $17.39M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$98.41M↓ | -$96.44M↑ | -$115.29M↑ | -$140.54M↓ | -$101.53M |
| Net Income | -$93.05M↓ | -$92.93M↑ | -$110.75M↓ | $59.32M↑ | -$98.96M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psori...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.87%
Volume
Today's trading volume
3.08M
Recent News
Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
Alumis stock presents a sharp disconnect between recent share price swings and what broad valuation checks suggest. After a very strong 1 year return, the company now screens as expensive on the wider metrics, even after a steep pullback following mixed trial news. Alumis has delivered a 121.2% return over the past year, which puts extra focus on whether the current price already reflects much of the good news investors expect. The recent Phase 2b LUMUS trial setback in lupus, together with...
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
In early September 2026, Alumis reported that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet primary and secondary endpoints in the overall patient population, despite a favorable safety profile over 48 weeks. An important finding was that a prespecified subgroup of patients with a high interferon gene signature showed robust clinical responses, supporting Alumis’ plan to pursue biomarker-driven Phase 3 development and an NDA in...
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
Alumis (ALMS) is back in focus after reporting that envudeucitinib missed primary and secondary endpoints in the Phase 2b LUMUS lupus trial, while a predefined interferon gene signature high subgroup showed stronger clinical responses. That mixed trial readout has gone hand in hand with sharp share price volatility, with a 7 day share price return of down 56.18% and a 30 day share price return of down 60.38%. Alumis still shows a year to date share price return of 15.58% and a 1 year total...
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints
Alumis (NasdaqGS: ALMS) reported that its lead drug envudeucitinib did not meet primary or secondary endpoints in a Phase 2b lupus trial. The company highlighted strong efficacy and safety signals in a genetically defined IFNGS high subgroup of lupus patients within the study. Alumis plans to continue developing envudeucitinib and discuss potential regulatory paths for broader immune mediated indications based on the subgroup data. This update on Alumis shows how targeted drug development...
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State